

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**PROPOSED ADOPTION OF
THE AMENDED MEMORANDUM AND ARTICLES OF ASSOCIATION**

This announcement is made by Genscript Biotech Corporation (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to amend the existing second amended and restated memorandum and articles of association of the Company (the “**M&A**”) to, amongst others, (i) bring the M&A in line with the amendments made to the applicable laws of the Cayman Islands and the Listing Rules, in particular Appendix 3 to the Listing Rules regarding the core shareholder protection standards, (ii) allow general meetings of the Company to be held as a hybrid meeting or electronic meeting where shareholders of the Company (the “**Shareholders**”) may attend by electronic means in addition to as a physical meeting where shareholders attend in person, and (iii) adopt certain consequential and housekeeping amendments (the “**Proposed Amendments**”). As such, the Board proposes to adopt the third amended and restated memorandum and articles of association (the “**Amended M&A**”) containing the Proposed Amendments in substitution for, and to the exclusion of, the existing M&A.

The adoption of the Amended M&A is subject to the approval of the Shareholders by way of a special resolution at the forthcoming annual general meeting (“**AGM**”) of the Company, and will become effective upon the approval by the Shareholders at the AGM. A circular containing, among other things, further details concerning the Proposed Amendments and the proposed adoption of the Amended M&A, together with the notice of the AGM and the proxy form, will be despatched to the Shareholders in due course.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 6 April 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*